Newer catecholamines for treatment of heart failure and shock: an update on dopamine and a first look at dobutamine.
D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use; D000328:Adult; D000818:Animals; D002395:Catecholamines / Q000627:therapeutic use*; D003326:Coronary Circulation / Q000187:drug effects; D004280:Dobutamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004298:Dopamine / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D018492:Dopamine Antagonists; D004305:Dose-Response Relationship, Drug; D006333:Heart Failure / Q000188:drug therapy*; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009206:Myocardium / Q000378:metabolism; D010101:Oxygen Consumption / Q000187:drug effects; D011652:Pulmonary Circulation / Q000187:drug effects; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects; D011943:Receptors, Adrenergic, beta / Q000187:drug effects; D011954:Receptors, Dopamine / Q000187:drug effects; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D014665:Vasodilator Agents / Q000627:therapeutic use
D000317:Adrenergic alpha-Antagonists; D002395:Catecholamines; D018492:Dopamine Antagonists; D011942:Receptors, Adrenergic, alpha; D011943:Receptors, Adrenergic, beta; D011954:Receptors, Dopamine; D014665:Vasodilator Agents; D004280:Dobutamine; D004298:Dopamine